Shares mag. recommending this stock this week. Is this going to be our killer this christmas!!!! any comments anyone?????

Announcement today: Gartmore declare a 10.3% (49,977,758 shares) holding in CEN.

True Ludlow,but its had NO impact on the SP!!,
Market knows more than i do.

.

Hope you are right!!,but for now its not good.

capetown, the 32% reduction in dry retching/vomiting for European PIII M6G in comparison to morphine was still an encouraging result. Have you sold?

Ludlow,i agree with all that you are saying,I have NOT sold out,just simply stating that the sp is grimm,i will add @6 p to my other holding and wait.

CeNeS Investor Chronicle 23rd February. I read with interest the report page 14 on CeNeS.. However I disagree with Karl Keegan, analyst at Canaccord Adams who has downgraded from buy to hold.. As he says the nausea reduction was not statistically significant and that CeNeS could have to do another trial..

Trials delivered Stong results with CeNeS saying that M6G showed significant reduction in post operative nausea and vomiting compared to morphine.. That on its own is a major benefit to patients.. Its bad enough being in pain.. Reduction of nausea and vomiting is a key factor.. Thank you CeNeS for all the trials that your company has undertaken to prove that M6G is the better drug.. For pain relief with reduced side effects..

With the Gartmore investment CeNeS will soon bounce back...

So why has the share price bombed again this morning

CEN Level 2:

5 market makers blue.

capetown
I agree not worried I will also add if it dips any lower.

Much better day today,anothe few mill buys and we might get a tick up.

Having spoken to the CEN, my understanding is they have other statistically significant data that supports a reduction in nausea but they did not choose those particular data measurements as one of the two primary endpoints. Obviously the statistically significant 32% reduction in retching/vomiting, which was the other primary endpoint, still stands.

barclays now have 14% holding!!!!

Nice to see some good news on a s**t day!

.

Objective Capital have issued a new report on CEN saying the failure to meet the primary endpoint for PIII M6G in the nausea indication, will necessitate a further Phase 3 trial (probably as part of a US Phase 3 trial) and delay launch until 2010.

Looks like 4.50/5.oo back on the cards then,and back to bottom draw.

Alan Goodman, Chairman of CeNeS, said:

"CeNeS has taken a major step forward in the development of M6G and is now well
placed to successfully commercialise its lead asset. The partnering process has
begun and the Company is well positioned to deliver significant value to
shareholders in the near-term."

From the finals. We shall see. Only time will tell.

Agree long term bottom drawer!

Some news-

FDA approves IND on Lead Product M6G

Cambridge, UK, 26th April 2007 - CeNeS Pharmaceuticals plc (LSE: CEN), the Cambridge based biopharmaceutical company, today announces that the United States Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for the clinical development of morphine-6-glucuronide (M6G), its novel drug for the treatment of post-operative pain. Earlier this year, CeNeS announced results of a Phase III study of M6G in Europe in over 500 patients with post-operative pain. The study demonstrated that M6G provided equivalent pain relief to morphine but induced significantly less post-operative nausea and vomiting (PONV).
The opening trial under this IND will be a Phase I pharmacokinetic study in volunteers. This study is required by the FDA as is an additional pre-clinical toxicology analysis before progressing to Phase III trials. CeNeS is currently completing the protocol design of the first US Phase III trial. The filing of the IND enhances the package of data already available to potential US partners for review.
Neil Clark, Chief Executive of CeNeS, said:

"The FDAs approval of our IND application for M6G is a major landmark in CeNeS clinical development programme. North America is an attractive market for our drug candidate and M6G is clearly positioned to be a genuine alternative to standard morphine therapy."